Abstract
Purpose
To assess the impact on visual acuity of delays between diagnosis and treatment in patients with subfoveal neovascular age-related macular degeneration (NV-AMD) and to evaluate NV-AMD patients' emotional status before therapy initiation.
Methods
This retrospective, multicenter, epidemiological study included newly diagnosed NV-AMD patients registered in the Spanish national health system and referred to regional health centers for evaluation/treatment by a retinal specialist from 09/2005 to 03/2006. Records were reviewed and data abstracted at referring physicians' offices (diagnosis visit) and regional health centers (treatment visit). Treatment was at physicians' discretion. The Hospital Anxiety and Depression Scale was administered at the treatment visit (before therapy).
Results
Median time from the diagnosis to treatment visit was 2.3 months (95% confidence interval: 0.2–10.8 months). Vision loss had progressed at the treatment visit with a doubling in the percentage of patients with a visual acuity of 20/400 or worse (from 12.4 to 24.7%). The decrease in visual acuity from the diagnosis to the treatment visit was highly statistically significant (P<0.0001) as was the correlation between months to treatment and visual acuity change (r=0.5234, P<0.0001). Time from the diagnosis to the treatment visit remained a significant predictor of progressive vision loss when visual acuity at diagnosis and change in lesion size between diagnosis and treatment were controlled (P<0.0001). Patients with more severe vision loss prior to treatment tended to report more depression.
Conclusions
Delayed treatment of patients newly diagnosed with NV-AMD is associated with substantial visual acuity loss.
Similar content being viewed by others
Login or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ambati J, Ambati BK, Yoo SH, Sakurai E, Lynn BC, Kuziel WA et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257–293.
Ferris III FL . Senile macular degeneration: review of epidemiologic features. Am J Epidemiol 1983; 118: 132–151.
Ferris III FL, Fine SL, Hyman L . Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640–1642.
Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108: 1893–1900.
DeCarlo DK, Scilley K, Wells J, Owsley C . Driving habits and health-related quality of life in patients with age-related maculopathy. Optom Vis Sci 2003; 80: 207–213.
Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM . Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999; 128: 45–53.
Rovner BW, Casten RJ, Tasman WS . Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol 2002; 120: 1041–1044.
Scott IU, Feuer WJ, Jacko JA . Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol 2002; 133: 350–357.
Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI . The psychosocial impact of macular degeneration. Arch Ophthalmol 1998; 116: 514–520.
Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RR, Mitchell P . Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004; 45: 71–76.
Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815–827.
Bonastre J, Le Pen C, Soubrane G, Qtel G . The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21: 181–190.
Hopley C, Salkeld G, Wang JJ, Mitchell P . Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004; 88: 450–454.
Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S . Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005; 40: 313–319.
Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220–1231.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report no. 1. Arch Ophthalmol 1999; 117: 1329–1345.
Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–2816.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992–1001.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham Jr ET, Goldbaum M, Guyer DR et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508–1521.
Klaver CC, Assink JJ, van Leeuwen R, Wolfs RC, Vingerling JR, Stijnen T et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2001; 42: 2237–2241.
Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205–210.
American Academy of Ophthalmology. Preferred Practice Pattern: Age-Related Macular Degeneration. American Academy of Ophthalmology: San Francisco, 2006, p 4.
Shah S, Zlateva G, Zhou S, Javitt JC . Comparison of comorbid conditions between wet AMD patients and a control cohort in the Medicare Population. Invest Ophthalmol Vis Sci 2006; 47 (E-abstract 2209).
Acknowledgements
This study was funded by Pfizer Inc., New York. Editorial support, including contributing to the development of the manuscript and styling the paper for journal submission, was provided by Dr Jane Murphy of Zola Associates and was funded by Pfizer Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arias, L., Armadá, F., Donate, J. et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 23, 326–333 (2009). https://doi.org/10.1038/sj.eye.6703053
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.eye.6703053
Keywords
This article is cited by
-
Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
Cost Effectiveness and Resource Allocation (2022)
-
Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study
Eye (2022)
-
PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
-
Gründe für Therapieverzögerung und -abbruch bei altersabhängiger Makuladegeneration
Der Ophthalmologe (2018)
-
Clinically applicable deep learning for diagnosis and referral in retinal disease
Nature Medicine (2018)